Dyno-ahq

Dyno-ahq is an engineered adeno-associated virus (AAV) capsid developed by Dyno Therapeutics using its proprietary AI-powered CapsidMap™ platform. Designed specifically for central nervous system (CNS) delivery, Dyno-ahq aims to overcome the biological barriers that limit traditional gene therapy vectors, such as the blood-brain barrier. By utilizing machine learning to optimize the capsid's protein sequence, Dyno Therapeutics seeks to achieve high-efficiency transduction of neuronal and glial cells following systemic administration, while simultaneously reducing liver sequestration and pre-existing immune recognition. This candidate is part of a broader portfolio of synthetic capsids intended to enable more effective and safer gene therapies for a variety of neurological disorders.

Other names

Dyno-ahq